Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $137,219.20 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This represents a 0.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Vir Biotechnology Trading Down 3.0 %

VIR stock opened at $12.10 on Friday. The firm has a market capitalization of $1.67 billion, a PE ratio of -3.09 and a beta of 0.51. Vir Biotechnology, Inc. has a 1-year low of $6.56 and a 1-year high of $14.45. The business’s 50 day simple moving average is $8.24 and its 200 day simple moving average is $8.36.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm’s revenue was down 9.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.22) earnings per share. As a group, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VIR. Charles Schwab Investment Management Inc. grew its holdings in Vir Biotechnology by 13.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock valued at $8,496,000 after buying an additional 136,087 shares in the last quarter. State Street Corp grew its holdings in Vir Biotechnology by 10.4% in the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after buying an additional 530,645 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in Vir Biotechnology in the 2nd quarter valued at $1,780,000. Point72 Hong Kong Ltd grew its holdings in Vir Biotechnology by 180.6% in the 2nd quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company’s stock valued at $174,000 after buying an additional 12,598 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Vir Biotechnology by 94.6% in the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock valued at $11,108,000 after buying an additional 606,804 shares in the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on VIR shares. HC Wainwright restated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Friday. Barclays decreased their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $10.00 to $20.00 in a research note on Thursday. Finally, JPMorgan Chase & Co. raised their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $37.80.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).